Phaseline

Companies › Frantz Viral Therapeutics

Frantz Viral Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 4 Phase 2; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Artesunate vaginal insert
Artemisinin derivative with antimalarial and anti-inflammatory properties; mechanism in CI
–Phase 2Vulvar Diseases; Anal High Grade Squamous Intraepithelial Lesion; CIN 2/3; Anal High-grade Squamous Intraepithelial LesionDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06075264Artesunate vaginal insertPhase 2Vulvar DiseasesInfectious diseaseDec 2026
NCT05555862Artesunate vaginal insertPhase 2Anal High Grade Squamous Intraepithelial LesionInfectious diseaseDec 2026
NCT04098744Artesunate vaginal insertPhase 2CIN 2/3Infectious diseaseDec 2026
NCT06206564Artesunate vaginal insertPhase 2Anal High-grade Squamous Intraepithelial LesionInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Amplexd Therapeutics Sano Chemicals Hyundai Bioscience KTH Biopharma Grand Theravac Life Sciences (Nanjing)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.